Press Releases for LJPC

Press Releases
La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders
La Jolla Pharmaceutical Company Receives Notice of Noncompliance With Nasdaq Stock Market Listing Requirement
BenchmarkJournal.Com Free Analyst Review for SQM, RY, ALGT, UTIW, SPPI and LJPC
La Jolla Pharmaceutical Company Announces Going Concern Opinion and Receipt of Nasdaq Staff Deficiency Letter
La Jolla Pharmaceutical Company Announces Reduction in Workforce and Evaluates Strategic Options
La Jolla Pharmaceutical Company Announces Negative Results of Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial
La Jolla Pharmaceutical Company to Present at BIO CEO & Investor Conference
BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
La Jolla Pharmaceutical Provides Update on Its Auction Rate Securities and Its Ongoing Riquent® Phase 3 “ASPEN” Lupus Trial
La Jolla Pharmaceutical Company Reports Third Quarter and Year-to-Date Financial Results
La Jolla Pharmaceutical Company to Present at UBS Global Life Sciences Conference
La Jolla Pharmaceutical Company to Present at Canaccord Adams Global Growth Conference
La Jolla Pharmaceutical Company Reports Second Quarter and Year-to-Date Financial Results
La Jolla Pharmaceutical Company to Present at Needham Biotechnology and Medical Technology Conference
La Jolla Pharmaceutical Company Announces Pricing of Common Stock and Warrant Unit Offering - Jun 2 2008 12:14AM
La Jolla Pharmaceutical Announces Positive 12-Month Interim Antibody Data and Provides Update for Ongoing Riquent(R) Phase 3 'ASPEN' Lupus Trial